Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,497 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Eating Beans on Metabolism

NCT06123208
View directory record Official record
Conditions
Overweight
Interventions
Whole cooked pinto bean, Pinto bean flour, Control
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
19 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Diabetes in the Elderly: Prospective Study

NCT01131052
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
Insulin Glargine, Insulin, Insulin glulisine
Drug
Lead sponsor
Guillermo Umpierrez
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047
View directory record Official record
Conditions
Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Anaheim, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid

NCT04315415
View directory record Official record
Conditions
Vocal Fold Palsy, Vocal Cord Paralysis, Vocal Cord Atrophy
Interventions
Silk Voice
Device
Lead sponsor
Sofregen Medical, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

NCT01089517
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030 plus Lucentis, Lucentis
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years to 100 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Platelet-Rich Fibrin in the Healing of Regional and Free Flaps

NCT04023474
View directory record Official record
Conditions
Head and Neck Disorder, Free Flap
Interventions
Platelet Rich Fibrin (PRF) Application
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study

NCT05769218
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CHORUS+, Standard of care
Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 25, 2026, 4:34 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 25, 2026, 4:34 AM EDT
Withdrawn Phase 4 Interventional

Levothyroxine in Pregnant SLE Patients

NCT01276782
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 25, 2026, 4:34 AM EDT
Not listed Phase 2 Interventional

Intra-articularInjection of Botulinum Toxin Type

NCT00211679
View directory record Official record
Conditions
Arthritis, Pain
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Oct 25, 2026, 4:34 AM EDT
Completed No phase listed Observational

ICATA Asthma Mechanistic Study

NCT00377390
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 20 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplementary Dietary Protein (21g Per Day) on Lean Mass and Strength in Sedentary, Adult Vegetarians

NCT04076982
View directory record Official record
Conditions
Muscle Weakness
Interventions
mung bean protein, control biscuit
Dietary Supplement · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breakfast Consumption and Energy Balance in Active Adult Males

NCT04862208
View directory record Official record
Conditions
Energy Intake, Substrate Utilization, Hormones, Satiety
Interventions
Maltodextrin supplement, Whey supplement, Water
Dietary Supplement
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 25, 2026, 4:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

NCT00454779
View directory record Official record
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions
Cisplatin, Panitumumab, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
82
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Duarte, California + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia

NCT00588159
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Diphenhydramine
Drug
Lead sponsor
Michelle Kinney
Other
Eligibility
45 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Soy Protein on Body Composition and General Health in Healthy Children

NCT02413710
View directory record Official record
Conditions
Generally Healthy Kids Consumption Soy Protein Foods as Part of Daily Diet
Interventions
Soy protein containing foods, Dietary Guidance
Other · Behavioral
Lead sponsor
DuPont Nutrition and Health
Industry
Eligibility
8 Years to 11 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 4:34 AM EDT